1651890-44-6 Usage
General Description
Pyridoclax is a novel small molecule inhibitor of Bcl-2, a protein that promotes cell survival and resistance to apoptosis, or programmed cell death. It is being investigated as a potential treatment for various types of cancer, where overexpression of Bcl-2 has been implicated in promoting tumor growth and resistance to chemotherapy. Preclinical studies have shown that Pyridoclax can induce apoptosis in cancer cells and synergize with other anticancer agents, making it a promising candidate for further clinical development. Research is ongoing to explore the potential of Pyridoclax as a targeted therapy for cancer and to better understand its mechanism of action and potential side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 1651890-44-6 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,5,1,8,9 and 0 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 1651890-44:
(9*1)+(8*6)+(7*5)+(6*1)+(5*8)+(4*9)+(3*0)+(2*4)+(1*4)=186
186 % 10 = 6
So 1651890-44-6 is a valid CAS Registry Number.
1651890-44-6Relevant articles and documents
Br vs. TsO Chemoselective Suzuki–Miyaura Cross-Coupling Reaction on Nicotinaldehyde Moiety for the Preparation of 2,3,5-Trisubstituted Pyridines
Hédou, Damien,Voisin-Chiret, Anne Sophie
, p. 3640 - 3649 (2020)
Br vs. TsO chemoselective pallado-catalyzed Suzuki–Miyaura reaction has been developed from the 5-bromo-2-tosyloxynicotinaldehyde for the preparation of polysubstituted pyridines. This methodology has been applied for the preparation of a terpyridine alde
MCL-1 MODULATING COMPOUNDS FOR CANCER TREATMENT
-
, (2015/09/28)
The invention relates to compounds of formula (I), and to their therapeutic use in the treatment of cancer : Wherein Y1, Y2, Ar1, Ar2, R1, R2, i, j, k, 1 are as defined in claim 1
